Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

	Related Links


	Educational Materials About Clinical Trials Clinical Trials: Questions and Answers Questions to Ask Your Doctor Drug Information from MedlinePlus

Arimidex Neoadjuvant in Operable Breast Cancer in Post-Menopausal Women

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase IV

Treatment

Active

Postmenopausal to 65

Pharmaceutical / Industry

1033MX/001
NCT00262535

Trial Description

Summary

To evaluate the efficacy, and safety of four months of treatment with anastrozole in an adjuvant setting, after that, conservative vs radical mastectomy clinical procedure is evaluated for next step surgical treatment, for post-menopausal women with hormonal receptors positive.

Eligibility Criteria

Inclusion Criteria:

Measurable tumor IIB IIIA

Post-menopausal women

Normal bone marrow

Life expectancy higher than six months

Exclusion Criteria:

Previous treatment with AI or tamoxifen

Uncontrolled endocrine conditions

Unstable angina

Bilateral disease

Trial Contact Information

Trial Lead Organizations/Sponsors

AstraZeneca Pharmaceuticals LP

AstraZeneca Mexico Medical Director, MD

Study Director

AstraZeneca Clinical Study Information
		Email: http://www.astrazeneca.com/node/emailtriage.aspx

Trial Sites

Mexico

Tlalpan

Research Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00262535
Information obtained from ClinicalTrials.gov on July 20, 2007

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.